{
  "symbol": "SPRC",
  "company_name": "Scisparc Ltd",
  "ir_website": "https://investor.scisparc.com/",
  "structured_data": [
    {
      "section_name": "Corporate Information",
      "links": [
        {
          "title": "Management Team",
          "url": "https://investor.scisparc.com/management-team/",
          "content": "[ Skip to content ](#content)\n\nNavigation Menu \n\n  * [Home](https://scisparc.com/)\n\n  * [About](https://scisparc.com/about/)\n\n  * [Product](https://scisparc.com/product/)\n\n  * [Investors](https://investor.scisparc.com/)\n\n  * [Science](https://scisparc.com/technology/)\n\n  * [Contact Us](https://scisparc.com/contact-us/)\n\n\n\n\n## Advisory Board\n\n  * Corporate Information\n    * [Management Team](https://investor.scisparc.com/management-team/)\n    * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n    * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n    * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n  * [Financial Info](https://investor.scisparc.com/)\n  * [Stock Data](https://investor.scisparc.com/stock-data/)\n  * [SEC Filings](https://investor.scisparc.com/sec-filings/)\n  * [Presentation](https://investor.scisparc.com/wp-content/uploads/2022/02/SciSparc_18022022.pdf)\n  * [Press Releases](https://investor.scisparc.com/press-releases/)\n  * [IR Alerts](https://investor.scisparc.com/ir-alerts/)\n\n\n\n[ ![](https://investor.scisparc.com/wp-content/uploads/2021/04/cropped-logo.png) ](https://investor.scisparc.com)\n\nX\n\n  * [Management Team](https://investor.scisparc.com/management-team/)\n  * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n  * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n  * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n\n\n\n## Amitay Weiss\n\n## Chairman\n\nMr. Weiss joined the Company in August 2020. He is founder and Chief Executive Officer of Amitay Weiss Management Ltd. Prior to forming his company, he held several positions at Bank Poalei Agudat Israel Ltd., most recently as Vice President of Business Marketing & Development. He currently chairs and serves as director on the boards of several public companies. Mr. Weiss earned his B.A in Economics from New England College, his M.B.A and LL.B from from Ono Academic College in Israel – a branch of the University of Manchester.\n\n## Adi Zuloff-Shani, PhD.\n\n## Chief Technologies Officer\n\nDr. Zuloff-Shani joined the Company in February 2016, bringing more than 20 years of experience as a research and development executive in the bio-tech industry and launching start-ups in the healthcare industry. Dr. Zuloff-Shani brought 2 products from bench to market and is currently leading the development of several pharmaceutical products designated to the US, EU and Israeli markets.\n\nPrior to joining us, she served as Vice President Development at Macrocure Ltd. (Nasdaq: “MCUR”) where she lead all research and development activities. Dr. Zuloff-Shani earned her Ph.D. in Human Biology and Immunology from Bar- Ilan University, Israel.\n\n## Oz Adler, CPA\n\n## Chief Financial Officer and Chief Executive Officer\n\nMr. Adler joined the Company in September 2017, and since April 2018 serves as the Company Chief Financial Officer .Mr. Adler has a wide variety of managerial, financial, tax and accounting experience. Prior to joining the Company, Mr. Adler was employed as a CPA at Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global. He currently chairs and serves as director on the boards of several private and public companies. Mr. Adler holds a B.A. in Accounting and Business Management from The College of Management, Israel.\n"
        },
        {
          "title": "Board of Directors",
          "url": "https://investor.scisparc.com/board-of-directors/",
          "content": "[ Skip to content ](#content)\n\nNavigation Menu \n\n  * [Home](https://scisparc.com/)\n\n  * [About](https://scisparc.com/about/)\n\n  * [Product](https://scisparc.com/product/)\n\n  * [Investors](https://investor.scisparc.com/)\n\n  * [Science](https://scisparc.com/technology/)\n\n  * [Contact Us](https://scisparc.com/contact-us/)\n\n\n\n\n## Board Of Directors\n\n  * Corporate Information\n    * [Management Team](https://investor.scisparc.com/management-team/)\n    * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n    * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n    * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n  * [Financial Info](https://investor.scisparc.com/)\n  * [Stock Data](https://investor.scisparc.com/stock-data/)\n  * [SEC Filings](https://investor.scisparc.com/sec-filings/)\n  * [Presentation](https://investor.scisparc.com/wp-content/uploads/2022/02/SciSparc_18022022.pdf)\n  * [Press Releases](https://investor.scisparc.com/press-releases/)\n  * [IR Alerts](https://investor.scisparc.com/ir-alerts/)\n\n\n\n[ ![](https://investor.scisparc.com/wp-content/uploads/2021/04/cropped-logo.png) ](https://investor.scisparc.com)\n\nX\n\n  * [Management Team](https://investor.scisparc.com/management-team/)\n  * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n  * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n  * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n\n\n\n## ITSCHAK SHREM\n\nMr. Shrem has served as our President since January 2022 and on our Board of Directors since August 2020. Mr. Shrem has our Chairman between August 2020 and January 2021 and brings more than 40 years of experience in financial markets and venture capital. In 1991, Mr. Shrem founded Dovrat Shrem Ltd., an investment banking, management and technology company. Prior to that, he spent 15 years at Clal Israel Ltd., where he served in various capacities, including chief operating officer, and was responsible for capital markets and insurance businesses. In 1993, Mr. Shrem founded Pitango Venture Capital Fund (formerly, Polaris) and served as a partner of Pitango Funds I, II and III. He has been the Managing Director of Yaad Consulting 1995 Ltd. since 1995.\n\nMr. Shrem currently serves on the board of directors of Rail Visions Ltd. and has previously served on the board of Tel-Aviv Sourasky Medical Center, the Weizman Institute Eden Spring Ltd., Nano Dimension Ltd., Ormat Industries Ltd., Retalix Ltd. and as Chairman of Sphera Funds Management Ltd. Mr. Shrem holds a B.A in Economics and Accounting from Bar-Ilan University and an M.B.A. from Tel-Aviv University.\n\n## AMITAY WEISS\n\nMr. Weiss has served as our Chief Executive Officer between August 2020 and January 2021and on our Board of Directors since August 2020. He is founder and Chief Executive Officer of Amitay Weiss Management Ltd. Prior to forming his company, he held several positions at Bank Poalei Agudat Israel Ltd., most recently as Vice President of Business Marketing & Development. He currently chairs and serves as director on the boards of several public companies. Mr. Weiss earned his B.A in Economics from New England College, his M.B.A and LL.B from from Ono Academic College in Israel – a branch of the University of Manchester.\n\n## LIOR VIDER\n\nMr. Vider has served on our Board of Directors since August 2020. He has been a Senior Investment Portfolio Manager at Epsilon Investment House Ltd. since 2010. Previous positions include Chief Investment Manager for Impact Investment Management Ltd., Chairman and member of the Investment Committee for Rahkia Capital Markets Ltd., Financial Desk Manager and Trader of trust funds for Ilanot Discount, and founded and managed Sponser.co.il, a financial portal specializing in services for investors. Mr. Vider holds a B.A in Industry and Management Engineering from Shenkar College in Israel.\n\n## MOSHE REVACH\n\nMr. Revach has served on our Board of Directors since August 2020. He is currently Deputy Mayor of the city of Ramat Gan, Israel, and has held the sports and government relations portfolios in the Ramat Gan municipality, and has serving in various positions with the Municipality since 2008. Mr. Revach serves as a director of L.L.N IT solutions, a wholly owned subsidiary of the Jewish Agency for Israel and of Biomedico Hadarim Ltd., and has served as a director of the RPG Economic Society and Jewish Experience Company on behalf of the Jewish Agency. Mr. Revach holds an LL.B from the Ono Academic College, Israel, and B.A in Management and Economics from the University of Derby.\n\n## LIAT SIDI\n\nMs. Sidi Has served on our Board of Directors since August 2020. She is currently Manager of Accounting for Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), and has previously served as an accountant for Panaxia Labs Israel Ltd. (TASE: PNAK), Soho Real Estate Ltd., Feldman-Felco Ltd. and the Eli Abraham Accounting Firm. Ms. Sidi completed tax, finance and accounting studies in Ramat Gan College of Accounting.\n\n## AMNON BEN SHAY\n\nMr. Amnon Ben Shay has served as our external director under the Companies Law since January 2021. Mr. Ben Shay has been serving as the chief financial officer of Hadar Hasharon Marketing and Distributions Ltd. since 2019. Additionally, Mr. Ben Shay currently serves on the board of directors of Value Capital One Ltd. (TASE: VALU) and previously served on the board of directors of Azorim Investments and Building Development Company Ltd. (TASE: AZRM) and B.G.I. Investments (1961) Ltd. (TASE: BGI). From 2017 to 2019, Mr. Ben Shay served as the chief financial officer of Fridenson Air & Ocean Ltd. From 2014 to 2017, he served as the chief financial officer of Abetrans Logistics Ltd. Prior to that, Mr. Ben Shay served as the chief financial officer of Isline Export and Import Services Ltd. from 2010 to 2013. Prior to the year 2009, Mr. Ben Shay served as the chief financial officer of several Israeli real estate investment groups. Mr. Ben Shay holds a B.A. in economics and business and an M.B.A in business, both from The Hebrew University of Jerusalem, Israel, and an accounting certificate from The College of Management Academic Studies, Israel.\n\n## ALON DAYAN\n\nMr. Alon Dayan has served as our external director under the Companies Law since January 2021. Mr. Dayan is the founder of L1-Systems Ltd. and has been serving as its chief executive officer since 2015. Since 2018, Mr. Dayan has served as the chief executive officer of Virtual Crypto Technologies Inc. (OTC: VBIX), which he founded as well. Prior to that, he served as a business development manager at Elbit Systems Ltd. from 2006 to 2013. Mr. Dayan holds a B.A. in electronical engineering from Ariel University, Israel.\n"
        },
        {
          "title": "Scientific Advisory Board",
          "url": "https://investor.scisparc.com/advisory-board/",
          "content": "[ Skip to content ](#content)\n\nNavigation Menu \n\n  * [Home](https://scisparc.com/)\n\n  * [About](https://scisparc.com/about/)\n\n  * [Product](https://scisparc.com/product/)\n\n  * [Investors](https://investor.scisparc.com/)\n\n  * [Science](https://scisparc.com/technology/)\n\n  * [Contact Us](https://scisparc.com/contact-us/)\n\n\n\n\n## Scientific Advisory Board\n\n  * Corporate Information\n    * [Management Team](https://investor.scisparc.com/management-team/)\n    * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n    * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n    * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n  * [Financial Info](https://investor.scisparc.com/)\n  * [Stock Data](https://investor.scisparc.com/stock-data/)\n  * [SEC Filings](https://investor.scisparc.com/sec-filings/)\n  * [Presentation](https://investor.scisparc.com/wp-content/uploads/2022/02/SciSparc_18022022.pdf)\n  * [Press Releases](https://investor.scisparc.com/press-releases/)\n  * [IR Alerts](https://investor.scisparc.com/ir-alerts/)\n\n\n\n[ ![](https://investor.scisparc.com/wp-content/uploads/2021/04/cropped-logo.png) ](https://investor.scisparc.com)\n\nX\n\n  * [Management Team](https://investor.scisparc.com/management-team/)\n  * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n  * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n  * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n\n\n\n## Prof. Raphael Mechoulam\n\n****Prof. Raphael Mechoulam**** is a Professor Emeritus of the Department of Natural Products of the School of Pharmacy at the Faculty of Medicine of the Hebrew University of Jerusalem, and a member of the Israel Academy of Sciences and Humanities. Prof. Mechoulam’s research in the field of cannabis has led to his discovery of the endocannabinoid system. Additionally, Prof. Mechoulam was among the first to complete the total synthesis of the major plant cannabinoids, THC, cannabidiol, cannabigerol, and others, and also played a key role in the isolation of the first described endocannabinoid anandamid. Prof. Mechoulam’s research interests are in the chemical and biological activity of natural products and medicinal agents, of which his primary contributions are in the field of the constituents of cannabis, about which Prof. Mechoulam has published extensively. Prof. Mechoulam has received amongst others, the Israel Prize in 2000, the European College of Neuropsychopharmacology Lifetime Achievement Award in 2006 and the Rothschild Prize in 2012.\n\n## Dr. Yossi Tam\n\n****Dr. Yossi Tam**** received his B.Med.Sc., M.Sc., Ph.D. and D.M.D. from the Hebrew University of Jerusalem. Dr. Tam did his postdoctoral training at the National Institutes of Health (NIH), and in 2011, became a staff scientist at the NIH. In June 2014, Dr. Tam moved to the Hebrew University of Jerusalem, where he heads the Obesity and Metabolism Laboratory at the Institute for Drug Research, and focuses on targeting the endocannabinoid (eCB) system for Obesity, Diabetes and the metabolic syndrome. Dr. Tam also serves as the Director of the Hebrew University’s Multidisciplinary Center on Cannabinoid Research and a Scientific Advisory Board Member of several biotech companies, which develop a portfolio of non-psychoactive cannabinoid and cannabinoid modulating medicines for unmet market needs. Dr. Tam won major national and international grants and authored over 40 peer-reviewed papers in leading journals, and two book chapters.\n\n## Prof. Elon Eisenberg\n\n****Prof. Elon Eisenberg**** , is the Dean of the Faculty of Medicine at the Technion – Israel Institute of Technology. Prof. Eisenberg is a Professor of Neurology and Pain Medicine at the Faculty of Medicine and holds the Otto Barth Family Academic Chair in Biomedical Science. Prof. Eisenberg graduated from Sackler School of Medicine, Tel-Aviv University in Israel. Prof. Eisenberg completed a residency in Neurology, at Rambam Medical Center, Haifa, Israel, and Neurology – Pain Fellowship at Massachusetts General Hospital, Harvard Medical School in Boston, USA. Prof. Eisenberg has been the director of the Institute of Pain Medicine at Rambam Health Care Campus, Haifa, Israel, and the President of the Israeli Pain Association. Prof. Eisenberg is currently the director of the Pain Research Unit at the Institute of Pain Medicine, Rambam Health Care Campus. H Prof. Eisenberg’s main areas of research include mechanisms and treatment of pain with special emphasis on neuropathic pain, CRPS, cancer pain, opioids and cannabinoids. Prof. Eisenberg has published about two-hundred articles, book chapters and other manuscripts in various areas of pain.\n\n## Prof. James Leckman, M.D.\n\n****Prof. James Leckman, M.D.**** is the Neison Harris Professor of Child Psychiatry, Psychiatry, Psychology and Pediatrics at Yale University. Prof. Leckman has served as director of Research for the Yale Child Study Center for more than twenty years. Prof. Leckman’s current research involves exploring whether the strengthening of families and the enhancement of childhood development leads to peaceful results and the prevention of violence. Additionally, Prof. Leckman has a longstanding interest in Tourette syndrome and OCD. Prof. Leckman is the author or co-author of over 430 original articles published in peer-reviewed journals, twelve books, and 140 book chapters.\n\n## Prof. Michael Davidson\n\n****Prof. Michael Davidson**** currently serves, among other things, as Chairman of the Stuckinski Centre for Alzheimer’s Disease Research in Ramat Gan. Prof. Davidson is also the editor of European Neuropsychopharmacology. Prof. Davidson served as Chief Psychiatrist at the Department of Psychiatry of the Sheba Medical Centre in Tel-Hashomer for six years. Prof. Davidson holds a professorship at the Sackler School of Medicine of Tel Aviv University and a secondary appointment at the Mount Sinai School of Medicine in New York. Prof. Davidson is considered an international expert on Alzheimer’s and is the author of approximately 300 publications in scientific literature.\n\n[ Next Page ](https://investor.scisparc.com/advisory-board-2)\n"
        },
        {
          "title": "Governance Documents",
          "url": "https://investor.scisparc.com/governance-documents/",
          "content": "[ Skip to content ](#content)\n\nNavigation Menu \n\n  * [Home](https://scisparc.com/)\n\n  * [About](https://scisparc.com/about/)\n\n  * [Product](https://scisparc.com/product/)\n\n  * [Investors](https://investor.scisparc.com/)\n\n  * [Science](https://scisparc.com/technology/)\n\n  * [Contact Us](https://scisparc.com/contact-us/)\n\n\n\n\n## GOVERNANCE DOCUMENTS\n\n  * Corporate Information\n    * [Management Team](https://investor.scisparc.com/management-team/)\n    * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n    * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n    * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n  * [Financial Info](https://investor.scisparc.com/)\n  * [Stock Data](https://investor.scisparc.com/stock-data/)\n  * [SEC Filings](https://investor.scisparc.com/sec-filings/)\n  * [Presentation](https://investor.scisparc.com/wp-content/uploads/2022/02/SciSparc_18022022.pdf)\n  * [Press Releases](https://investor.scisparc.com/press-releases/)\n  * [IR Alerts](https://investor.scisparc.com/ir-alerts/)\n\n\n\n[ ![](https://investor.scisparc.com/wp-content/uploads/2021/04/cropped-logo.png) ](https://investor.scisparc.com)\n\nX\n\n  * [Management Team](https://investor.scisparc.com/management-team/)\n  * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n  * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n  * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n\n\n\n###### [Sci Sparc - Code of Ethics and Conduct](https://investor.scisparc.com/wp-content/uploads/2022/01/Scisparc-CodeofEthicsandConductAdoptedonOctober142020Clean.docx)\n\n[ ](https://investor.scisparc.com/wp-content/uploads/2022/01/Scisparc-CodeofEthicsandConductAdoptedonOctober142020Clean.docx)\n\n###### [US Tax Form 8937](https://investor.scisparc.com/wp-content/uploads/2024/08/SciSparc-Form89374873-2696-1861.2.pdf)\n\n[ ](https://investor.scisparc.com/wp-content/uploads/2024/08/SciSparc-Form89374873-2696-1861.2.pdf)\n\n###### [Annex to Tax Form 8937](https://investor.scisparc.com/wp-content/uploads/2024/08/SciSparc-Reverse-Share-Split-Form-8937-Attachment-4868-0247-8021.2.pdf)\n\n[ ](https://investor.scisparc.com/wp-content/uploads/2024/08/SciSparc-Reverse-Share-Split-Form-8937-Attachment-4868-0247-8021.2.pdf)\n\n###### [Annex to Tax Form 8937](https://investor.scisparc.com/wp-content/uploads/2024/07/SciSparc-Reverse-Share-Split-Form-8937.pdf)\n\n[ ](https://investor.scisparc.com/wp-content/uploads/2024/07/SciSparc-Reverse-Share-Split-Form-8937.pdf)\n"
        }
      ]
    },
    {
      "section_name": "Financial Info",
      "links": [
        {
          "title": "Stock Data",
          "url": "https://investor.scisparc.com/stock-data/",
          "content": "[ Skip to content ](#content)\n\nNavigation Menu \n\n  * [Home](https://scisparc.com/)\n\n  * [About](https://scisparc.com/about/)\n\n  * [Product](https://scisparc.com/product/)\n\n  * [Investors](https://investor.scisparc.com/)\n\n  * [Science](https://scisparc.com/technology/)\n\n  * [Contact Us](https://scisparc.com/contact-us/)\n\n\n\n\n## Stock Data\n\n  * Corporate Information\n    * [Management Team](https://investor.scisparc.com/management-team/)\n    * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n    * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n    * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n  * [Financial Info](https://investor.scisparc.com/)\n  * [Stock Data](https://investor.scisparc.com/stock-data/)\n  * [SEC Filings](https://investor.scisparc.com/sec-filings/)\n  * [Presentation](https://investor.scisparc.com/wp-content/uploads/2022/02/SciSparc_18022022.pdf)\n  * [Press Releases](https://investor.scisparc.com/press-releases/)\n  * [IR Alerts](https://investor.scisparc.com/ir-alerts/)\n\n\n\n[ ![](https://investor.scisparc.com/wp-content/uploads/2021/04/cropped-logo.png) ](https://investor.scisparc.com)\n\nX\n\n  * [Quote](https://investor.scisparc.com/stock-data/)\n  * [Charts](https://investor.scisparc.com/charts/)\n  * [Historical Data](https://investor.scisparc.com/historical-data/)\n\n\n\n[ ](#)[Financial Market Data](https://www.quotemedia.com/coverage) copyright © 2020 [QuoteMedia](https://www.quotemedia.com). Data delayed 15 minutes unless otherwise indicated (view [delay times](https://www.quotemedia.com/legal/tos/#times) for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. [Market Data](https://www.quotemedia.com/coverage) powered by [QuoteMedia](https://www.quotemedia.com). [Terms of Use](https://www.quotemedia.com/legal/tos/).\n\n[![QuoteMedia logo](//www.quotemedia.com/footer/logo.png)](https://www.quotemedia.com)\n"
        },
        {
          "title": "SEC Filings",
          "url": "https://investor.scisparc.com/sec-filings/",
          "content": "[ Skip to content ](#content)\n\nNavigation Menu \n\n  * [Home](https://scisparc.com/)\n\n  * [About](https://scisparc.com/about/)\n\n  * [Product](https://scisparc.com/product/)\n\n  * [Investors](https://investor.scisparc.com/)\n\n  * [Science](https://scisparc.com/technology/)\n\n  * [Contact Us](https://scisparc.com/contact-us/)\n\n\n\n\n## SEC Filings\n\n  * Corporate Information\n    * [Management Team](https://investor.scisparc.com/management-team/)\n    * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n    * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n    * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n  * [Financial Info](https://investor.scisparc.com/)\n  * [Stock Data](https://investor.scisparc.com/stock-data/)\n  * [SEC Filings](https://investor.scisparc.com/sec-filings/)\n  * [Presentation](https://investor.scisparc.com/wp-content/uploads/2022/02/SciSparc_18022022.pdf)\n  * [Press Releases](https://investor.scisparc.com/press-releases/)\n  * [IR Alerts](https://investor.scisparc.com/ir-alerts/)\n\n\n\n[ ![](https://investor.scisparc.com/wp-content/uploads/2021/04/cropped-logo.png) ](https://investor.scisparc.com)\n\nX\n\n[Click here to view the proxy materials for September 15, 2022, Annual General Meeting of Shareholders](https://www.sec.gov/Archives/edgar/data/0001611746/000121390022046865/ea164212-6k_scisparcltd.htm)\n\n[ ](#)[Financial Market Data](https://www.quotemedia.com/coverage) copyright © 2020 [QuoteMedia](https://www.quotemedia.com). [Market Data](https://www.quotemedia.com/coverage) powered by [QuoteMedia](https://www.quotemedia.com). US Filings by Morningstar. [Terms of Use](https://www.quotemedia.com/legal/tos/). \n\n[![QuoteMedia logo](//www.quotemedia.com/footer/logo.png)](https://www.quotemedia.com)\n"
        },
        {
          "title": "Presentation",
          "url": "https://investor.scisparc.com/wp-content/uploads/2022/02/SciSparc_18022022.pdf",
          "content": "CORPORATE\nPRESENTATION\nNasdaq:SPRC\nFebruary 2022\nSAFE HARBOR STATEMENT\nThispresentationofSciSparcLtd.(the“Company”)contains“forward-lookingstatements”withinthemeaningofthePrivateSecuritiesLitigationReformActandother\nsecuritieslaws.Wordssuchas“expects,”“anticipates,”“intends,”“plans,”“believes,”“seeks,”“estimates”andsimilarexpressionsorvariationsofsuchwordsareintended\ntoidentifyforward-lookingstatements.Forexample,theCompanyisusingforward-lookingstatementswhenitdiscussesstatementsrelatingtoitsobjectives,plans,and\nstrategies,theexpectedtimingoftrials,itsproductpipeline,theresearch,development,anduseofitsplatformtechnologies,productsandproductcandidates,andall\nstatements(otherthanstatementsofhistoricalfacts)thataddressactivities,events,ordevelopmentsthattheCompanyintends,expects,projects,believes,oranticipates\nwillormayoccurinthefuture.Forward-lookingstatementsarenothistoricalfacts,andarebaseduponmanagement’scurrentexpectations,beliefsandprojections,\nmanyofwhich,bytheirnature,areinherentlyuncertain.Suchexpectations,beliefsandprojectionsareexpressedingoodfaith.However,therecanbenoassurancethat\nmanagement’sexpectations,beliefsandprojectionswillbeachievedandactualresultsmaydiffermateriallyfromwhatisexpressedinorindicatedbytheforward-looking\nstatements.Forward-lookingstatementsaresubjecttorisksanduncertaintiesthatcouldcauseactualperformanceorresultstodiffermateriallyfromthoseexpressedin\ntheforward-lookingstatements.ForamoredetaileddescriptionoftherisksanduncertaintiesaffectingtheCompany,referenceismadetotheCompany’sreportsfiled\nfromtimetotimewiththeSecuritiesandExchangeCommissionincluding,butnotlimitedto,therisksdetailedintheCompany’sannualreportonForm20-Ffortheyear\nendedDecember31,2020.Forward-lookingstatementsspeakonlyasofthedatethestatementsaremade.TheCompanyassumesnoobligationtoupdateforward-looking\nstatementstoreflectactualresults,subsequenteventsorcircumstances,changesinassumptionsorchangesinotherfactorsaffectingforward-lookinginformationexceptto\ntheextentrequiredbyapplicablesecuritieslaws.IftheCompanydoesupdateoneormoreforward-lookingstatements,noinferenceshouldbedrawnthattheCompanywill\nmakeadditionalupdateswithrespecttheretoorwithrespecttootherforward-lookingstatements.\n2\nSciSparc\nNASDAQ:SPRC\nWe are revolutionizing cannabinoid-based\ntreatments bydeveloping proprietary pharmaceuticals\nthatincrease patients’safetybyreducingdoses while\nmaintainingeffectiveness\n3\nSciSparc AT A GLANCE\nRecent Updates Key Stats\n• New Leadership since August 2020 • Market Cap: $16.3*\n• Accelerated R&D activities • Shares Outstanding: 3.1M\n• Strengthened IPportfolio: Newpatents granted • Float:2.7M\n(U.S., Japan and Australia) • Founds raised during the\n• ReceivedTM(Trademark)intheU.S.forCannAmide,our past 18 months: $17M\nproprietaryPalmitoylethanolamideformulation, one of • 0Debt\nthekeycompounds ofour proprietarycombinations\nScientific Programs *As of February 14, 2022\n4\nTECHNOLOGY\nPlatformSCI-110 PlatformSCI-160\nTHC(Tetrahydrocannabinol) + CB2Receptor (CB2R)\nPlatform SCI-210\nCannAmideTM Agonist\nCBD(Cannabidiol) +\nCannAmideTM\nTM\n> TouretteSyndrome(TS) Pain\n>AutismSpectrum Disorder(ASD)\n> Alzheimer’sDisease(AD)\nandagitation >StatusEpilepticus (SE)\n> Obstructive Sleep Apnea(OSA)\n5\nINTELLECTUAL PROPERTY\nOwnstrong 9patentfamilies 8grantedpatents Additional pending\nIPportfolio (5intheU.S.) patent applications\n(Europe, China\nJapan and more)\n6\nOUR METHODOLOGY\nUtilizingtheEndocannabinoid\nsystem to affect the central\nCombiningCannAmideTM*with\nnervoussystem (CNS)\nDifferentcannabinoids\nIdeal solution\nReducing cannabinoids doses Formulation\nMaintainingtherapeuticefficacy\nIncreasingsafety\n7\n*CannAmideTM-SciSparc proprietary formulation based on active pharmaceutical ingredient Palmitoyletanolamide\nMARKET OPPORTUNITY\nTourette Alzheimer’s\nSyndrome (TS) Disease (AD)\nStatus\n$80Min 2019andis expected toreach Epilepticus The global Alzheimer’s therapeutics\n$98.7Mby2023 market is projected to reach $13.6B by\n2027 from $7.4B in 2019\nThe global epilepsy market size would\ngrowfrom$8.8Bin 2018to\n$9.5Btowards theendof2023\nAutism Spectrum Pain and\nDisorder (ASD) Inflammation\nThe global ASD therapeutics market was Theglobalchronicpaintreatment market\napproximately$3.3B in 2018 and isexpected was valuedat $77.8Bin2019\ntoreach approximately$4.6Bby2026\n8\n2021- 2022 PRE-CLINICAL & CLINICAL\nACHIEVEMENTS\nSCI–110 forAlzheimer's disease andAgitation-Recruitedfirstpatientforthe Company’sPhase IIa\nEnteredanagreementwithtwoclinicalsites:HannoverMedicalSchoolin Hannover,Germany,andTel-\nAvivSourasky MedicalCenter,inTel-Aviv,Israel,tofurtherthe Company’sPhaseIIbclinicalstudyfor\nSCI-110forpatientssufferingfrom TouretteSyndrome\nEntered intoagreementwith The Sheba Fund forHealth Services and Research,to perform a pre-\nclinicalstudyforthe evaluation of theCompany's SCI-210 drugdevelopmentprogram,for the\ntreatmentofStatusEpilepticus (SE)\nReceived positivetop-line resultsforthe Company’sproprietarycompound,SCI-160,ina controlled\npre-clinicaltrial onNeuropathicandPost-operative pain\n9\nFDA & EMA PHARMACEUTICAL PIPELINE STATUS\nCOMPOUND THERAPEUTICAREA PRECLINICAL PHASE I PHASE IIa PHASE IIb PHASE III\nPhaseIIb,\nSCI–110 TouretteSyndrome FPIQ22022\nSCI–110 AlzheimerDiseaseand Open label study,\nAgitation enrollmentinprogress\nSCI–210 StatusEpilepticus Firstresults\nH2 2022\nSCI–160 Pain Pre-IND Q3 2022,\nIND Q1 2023, Phase I H1 2023\nMEDICAL CANNABIS PHARMACEUTICAL ROUTE\nCOMPOUND THERAPEUTICAREA PRECLINICAL PHASE I PHASE IIa PHASE IIb PHASE III\nSCI–210 AutismSpectrum Disorder* Studyinitiation\nQ22022\nSCI-110–Proprietary combination of Tetrahydrocannabinol(THC)withCannAmide\nSCI-210 –Proprietary combination of Cannabidiol (CBD) with CannAmide\nSCI-160–ProprietaryCB2RagonistforthetreatmentofPain 10\n*Medical Cannabis Route\nNote:ForObstructiveSleepApnea,aftersuccessfulcompletionofphaseIiaclinicalstudy,searchingforstrategicpartnerforcontinuousdevelopment\nSCI-110 for TOURETTE SYNDROME(TS)\nPHASE IIA Led by Yale University\nAbout:TSisamovementandneurobehavioraldisordercharacterizedby\nmotorandvocalticsandishighlylinkedwithco-morbidities\nAsthecurrentlyusedmedicationsaremanagingonlyasmallnumberofdisease\nsymptomswith limitedefficacyandquestionablesafety,thereisaclearunmet\nmedicalneedforthemanagementof TS\nResultsfromourPhaseIIAclinicaltrialconductedinYaleUniversity:\nAnaverageticreductionof21%acrosstheentiresamplewithalmost40%ofthe\npatientsexperiencing greaterthan25%inticreductionasdefinedbyYGTSS-TTS(a\nclinician-ratedinstrumentconsideredasthegoldstandardforassessingticsinpatients\nwithTourette'sSyndrome)\nThemedicationwasgenerallywell-toleratedbysubjects\n12outofthe16subjectselectedtocontinueintoa24-weekextensionphaseofthetrial\n11\nSCI-110 for TS PHASE IIB\n•\nObjective: to evaluate the efficacy, safety and tolerability of the Company’s\nproprietary SCI-110 in a randomized, double-blind, placebo controlled, cross-\nover study\n•\nTwo medical centers: Hannover Medical School, Hannover, Germany and Tel-\nAviv SouraskyMedical Center, Tel-Aviv, Israel\n•\n1:1 ratio randomization to receive either SCI-110 or SCI-110 matched placebo\n(i.e., THC active, CannAmideTMplacebo)\n•\nDesign: 12 weeks treatment, washout period of 2 weeks, crossover for\nanother 12 weeks\n•\nPrimary efficacy: change in YGTSS-R-TTS1 as a continuous endpoint at week\n12 and week 26 of the double-blind phase compared to baseline\n•\nPrimary safety: absolute and relative frequencies of Serious Adverse Events\n(SAEs) for the whole population and separately for SCI-110 and placebo\ngroups\n12\nSCI-110 for ALZHEIMER’S DISEASE (AD) & AGITATION\nPhase IIA\nAbout: AD or mixed dementia (AD + Vascular Dementia) accounts for over 2/3 of all dementia(s)*\nwith majority of AD patients' manifest agitation and anxiety\nObjective: to evaluate the safety, tolerability and efficacy trend of SCI-110 in\nan open label study in patients with Alzheimer Disease (AD) and Agitation\nClinical site: Sophie & Abraham StuchynskiIsraeli Alzheimer's Medical Center\nIsrael\n20 patients will be treated with SCI-110 in a daily dose of up to 12.5mg\nTHC+800 mg PEA\nPrimary end point: safety and tolerability of SCI -110 in AD patients with\nagitation\nMain efficacy trend: The ability SCI -110 to ameliorate agitation in patients\nwith AD as measured by the Cohen Mansfield Agitation Inventory (CMAI)\n13\n* Types of dementia;Alzheimer’s disease.Alzheimer’s Research UKwebsite\nSCI-210 FOR AUTISM SPECTRUM DISORDER\n(ASD) Phase III*\nAbout: ASD is a condition related to brain development that impacts how a person perceives\nand socializes with others, causing problems in social interaction and communication.\nThe term \"spectrum\" in autism spectrum disorder refers to the wide range of symptoms and\nseverity\n• Study objective: to evaluate the safety, tolerability and efficacy of SCI-210 in children with\nASD in a randomized, double-blind, placebo controlled with cross-over study\n• Study site: the Clinical Research Center and Negev Autism Center and SorokaUniversity\nMedical Center, Be'er-Sheva, Israel\n• Study design: A 20-week, randomized double-blind placebo-controlled with cross-over\nclinical trial of 60 children\n• 30 participants for SCI-210, or SCI-210 placebo (CBD active, CannAmideTMplacebo) for 20\nweeks, Washout for 2 weeks, Crossed over for additional 20 weeks\n• Threeprimaryefficacyendpoints:\nThe Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire;\nThe Clinical Global Impressions-Improvement (CGI-I)performed bya clinician;\nThe effectivetherapeuticdose\n• Safety endpoint:Tolerabilityandadverseeffects 14\n*Medical Cannabis Route\nSCI-210 for STATUS EPILEPTICUS (SE)\nStatusEpilepticusis aseizurethatlastslongerthan5minutesoroneinwhichapersonhasmorethan1seizure\nwithina5-minuteperiod,withoutreturningtoanormallevelofconsciousnessbetweenepisodes\nThereislimitedpharmaceuticaltreatmentavailablefortreatingepilepsy,asaboutoneinthreepatientshavedrug-\nresistanceagainstepilepsy*\nInJune2018,theFDAapprovedpurifiedplant-derivedCBD(Epidiolex)forthetreatmentofseizuresassociatedwith\nLennox-GastautandDravetsyndromes(arareformofepilepsy)inpatientsagedtwoyearsandolder*\nButCBDmonotherapyhasseveraladverseeffects,themostcommonbeinglethargy,elevatedliverenzymes,\ndecreasedappetite,diarrhea,poorsleepqualityandinfections.Inaddition,CBDtherapyrequiresaconstant\nincreaseintherapeuticdosestostayeffectiveandleadstothedevelopmentoftolerance.\nTheCompanyintendstoutilizeitsproprietarySCI-210platform,combiningPEAwithCBDtreatmenttoachieve\nmaximumeffectwithminimaladversesideeffectsinEpilepsypatients\nPEASignificantlyIncreasesCBDEffects**:\nCBD was shown topreventfataccumulationinliver cellsinaconcentration\ndependent manner.PEA by itself didn’taffectfataccumulation\nAddition ofPEAtoCBDreducedtherequiredCBDconcentrationwhileachieving\nmaximaleffect\n*https://www.who.int/news-room/fact-sheets/detail/epilepsy 15\n**Basedonapre-clinicalstudyconductedbytheCompany\nSCI-160 FOR PAIN\nAninnovative and proprietaryCB2Receptor(CB2R) agonist\nformulationintendedforthe treatmentofpain.This specificCB2R\nagonistwassynthesized byProfessorRaphael Mechoulam, Ph.D.\nCB2 Receptorspecific agonists have been found to be involved in mediating\nanalgesic effects inthe peripheral nervoussystem,without significantside\neffects\nCB2R agonist donotcausetheundesirablecannabispsycho-activityeffect*\nTherapeutic effectsand potency have been successfully assessed in animal\nmodels**\nAftersuccessfulcompletionofpre-clinicalstudies,the Companywill file an\nFDAInvestigational New Drug (IND)PhaseIstudyapplication\n*Malan et al,Curr.Opinionin Pharmacol,2003\n**Basedonpre-clinical studiesconductedbytheCompany\n16\nSCI-160\nPRE-CLINICAL RESULTS\n120 VonFrey\n100\nInaVonFrey Test,ratswere\ne Vv oa nlu Fa rt ee yd\nF\nf io lar\nm\nta ec nt tile allodynia using a ytivin tio\ns\nwnit ea sr\n)% (\n68 00\nMorphine5mg/kg\nP efr fo icm ai cs yin ig\ns\nr be es tu tl ets\nr\nd the am no mns ot rr pa hte ina enalgesic thgir/tfa ep\nL\n40 SCI-160 0.1mg\n20\n0\n0 1 3\nStudy day\n17\nSCI-160\n250 HotPlate\nPRE-CLINICAL RESULTS\nMorphine5mg/kg\n200 SCI-1601mg/kg\nSCI-1600.1mg/kg\nRats were evaluatedfor pain response 0\nusingahot plate(52ºC) dezilamy a od t 150\nOne more, strongresults showanalgesic r )o %n 100\nefficacy better thanmorphine ytiviti\nts an ee\nHs(\n50\n0\n0 1 3 6 9\nStudy day\n18\nMANAGEMENT\nOzAdler Mr.Adlerhasexperienceinawidevarietyofmanagerial,financial,taxandaccountingpractices.From2012to2017,Mr.Adler\nCEO, CFO wasemployedasacertifiedpublicaccountantat KostForerGabbay& Kasierer,amemberofErnst&YoungGlobal.Mr.Adler\nholdsaB.A. degreeinAccountingandBusinessmanagementfromtheCollegeofManagement,Israel.\nAdi Zuloff-Shani, PhD Dr. Zuloff-Shani is a Research & Development professional with overall experience of about 20 years in the bio-tech and healthcare\nCTO industry. Dr. Zuloff-Shani has brought two products from bench to market; an immuno-cell-based product and a food-supplement and\nis currently leading the development of several pharmaceutical products designated to the U.S., EU, and Israeli markets. Dr. Zuloff-Shani\nhas extensive experience in research and development, manufacturing, clinical, and regulatory affairs. Dr. Zuloff-Shani holds a Ph.D. in\nhuman biology and immunology from Bar-Ilan University, Israel.\nAmitay Weiss Mr. Weiss serves as chairman of the board of directors of P.L.T Financial Services Ltd., as chairman of the board of directors of Matomy\nMedia Group Ltd. and as an external director of Cofix Group Ltd. In 2016, Mr. Weiss founded Amitay Weiss Management Ltd. and now\nChairman\nserves as its chief executive officer.\nItschak Shrem Mr.Shremhasmorethan40yearsofexperienceinfinancialmarketsandventurecapital.In1991,Mr.ShremfoundedDovrat\nPresident & Director ShremLtd.,aninvestmentbanking,managementand technologycompany.Priortothat,hespent15yearsatClalIsraelLtd.,\nwhereheservedinvariouscapacities,includingchiefoperatingofficer,andwasresponsibleforcapitalmarketsandinsurance\nbusinesses.In1993,Mr.ShremfoundedPitangoVentureCapitalFund(formerly,Polaris)andservedasapartnerofPitangoFunds\nI,IIandIII.HehasbeentheManagingDirectorofYaadConsulting1995Ltd.since1995.Mr.Shremcurrentlyservesontheboard\nofdirectorsofRailVisionsLtd.Previously,Mr.ShremservedontheboardofTel-AvivSouraskyMedicalCenter,theWeizmann\nInstituteEdenSpringLtd.,NanoDimensionLtd.,OrmatIndustriesLtd.,RetalixLtd.andaschairmanofSpheraFunds\nManagementLtd.Mr.ShremholdsaB.A.inEconomicsandAccountingfromBar-IlanUniversityandanM.B.A.fromTel-Aviv\nUniversity.\n19\nSciSparc SCIENTIFIC ADVISORY BOARD\nAwardwinning scientists\nProf. Raphael Mechoulam A Professor Emeritus of the School of Pharmacy at the Faculty of Medicine of the Hebrew University in Jerusalem\nA recipient of the Israel Prize\nProf. James Leckman A child Psychiatrist at Yale University\nServed as Director of the Child Study Center at Yale for over two decades\nAprominent international expert in the field of research and treatment of Tourette Syndrome\nDr. Michael Bloch Associate training director of the Child Study Center's Solnit Integrated Program, Yale School of Medicine\nNoted researcher on the study of Tourette Syndrome, obsessive-compulsive disorder and trichotillomania\nProf. Kirsten Muller-Vahl Professor of Psychiatry the Hannover Medical School, Germany\nRecognized as the leading researcher in the field of cannabinoid use in treatmentof Tourette Syndrome\nServed as a member of the scientific advisory board of the German Tourette Syndrome Association\nDr. Daniele Piomelli The Editor-in-Chief of Cannabis and Cannabinoid Research\nServes as Louise Turner Arnold Chair in Neurosciences\nProfessor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry at University of California,Irvine\nProf. Joseph Tam, Head of Metabolic Disorders Research\nDMD, PhD Hebrew University, Jerusalem\nA world leader in the field of Cannabis based solutions and is the Director of the Multidisciplinary Center on Cannabinoids in Israel\n20\nWHY INVEST IN SciSparc?\nProprietary Technology with cutting-edge drug combinations\naddressing large global unmet medical needs\nTwo Phase 2 Assets addressing multi-billion markets and a\nPending Phase 3* Clinical Trial\nAttractive valuation & well capitalized to execute 2022 objectives\nKey strategic partners, including leading universities, medical\ncenters and KOLs\nPreparing to file Investigational New Drug (IND) application in pain\nTop-line pre-clinical SE study results in Status Epilepticus expected\nin the second half of 2022\n21\n*Medical Cannabis Route\nThank You\nU.S. INVESTOR RELATIONS\nRedChip Companies Inc.\n1-800-REDCHIP (733-2447)\nSPRC@REDCHIP.COM\n22"
        },
        {
          "title": "Press Releases",
          "url": "https://investor.scisparc.com/press-releases/",
          "content": "[ Skip to content ](#content)\n\nNavigation Menu \n\n  * [Home](https://scisparc.com/)\n\n  * [About](https://scisparc.com/about/)\n\n  * [Product](https://scisparc.com/product/)\n\n  * [Investors](https://investor.scisparc.com/)\n\n  * [Science](https://scisparc.com/technology/)\n\n  * [Contact Us](https://scisparc.com/contact-us/)\n\n\n\n\n## Press Releases\n\n  * Corporate Information\n    * [Management Team](https://investor.scisparc.com/management-team/)\n    * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n    * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n    * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n  * [Financial Info](https://investor.scisparc.com/)\n  * [Stock Data](https://investor.scisparc.com/stock-data/)\n  * [SEC Filings](https://investor.scisparc.com/sec-filings/)\n  * [Presentation](https://investor.scisparc.com/wp-content/uploads/2022/02/SciSparc_18022022.pdf)\n  * [Press Releases](https://investor.scisparc.com/press-releases/)\n  * [IR Alerts](https://investor.scisparc.com/ir-alerts/)\n\n\n\n[ ![](https://investor.scisparc.com/wp-content/uploads/2021/04/cropped-logo.png) ](https://investor.scisparc.com)\n\nX\n"
        },
        {
          "title": "IR Alerts",
          "url": "https://investor.scisparc.com/ir-alerts/",
          "content": "[ Skip to content ](#content)\n\nNavigation Menu \n\n  * [Home](https://scisparc.com/)\n\n  * [About](https://scisparc.com/about/)\n\n  * [Product](https://scisparc.com/product/)\n\n  * [Investors](https://investor.scisparc.com/)\n\n  * [Science](https://scisparc.com/technology/)\n\n  * [Contact Us](https://scisparc.com/contact-us/)\n\n\n\n\n## IR ALERTS\n\n  * Corporate Information\n    * [Management Team](https://investor.scisparc.com/management-team/)\n    * [Board of Directors](https://investor.scisparc.com/board-of-directors/)\n    * [Scientific Advisory Board](https://investor.scisparc.com/advisory-board/)\n    * [Governance Documents](https://investor.scisparc.com/governance-documents/)\n  * [Financial Info](https://investor.scisparc.com/)\n  * [Stock Data](https://investor.scisparc.com/stock-data/)\n  * [SEC Filings](https://investor.scisparc.com/sec-filings/)\n  * [Presentation](https://investor.scisparc.com/wp-content/uploads/2022/02/SciSparc_18022022.pdf)\n  * [Press Releases](https://investor.scisparc.com/press-releases/)\n  * [IR Alerts](https://investor.scisparc.com/ir-alerts/)\n\n\n\n[ ![](https://investor.scisparc.com/wp-content/uploads/2021/04/cropped-logo.png) ](https://investor.scisparc.com)\n\nX\n"
        }
      ]
    }
  ]
}